Investigating Claims on Behalf of The Investors

The Schall Law Firm announces that it is investigating claims on the behalf of the investors in Alder BioPharmaceuticals, Inc. for potential breaches of fiduciary duty on the part of its directors in connection with the pending sale of the Company to H. Lundbeck A/S.

Alder is a biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialisation of novel therapeutic antibodies. The company’s mission is to forever change migraine treatment and give people with migraine their lives back.

The Schall Law Firm represents investors injured by stock fraud, breaches of fiduciary duty, and other management and director malfeasance.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website, or by email at brian@schallfirm.com.

The Schall Law Firm represents investors on a contingency fee basis. We are a securities class action firm singularly committed to recovering shareholder money from publicly traded companies that committ fraud.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm represents investors on a contingency fee basis. We are a securities class action firm singularly committed to recovering shareholder money from publicly traded companies that commit fraud.

Schall Law Firm announces investigation into Tyme Technologies, Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the US Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Tyme reported the results of its open-label Phase 2 study for its drug candidate SM-88 on January 18, 2019. The Company reported positive results, stating SM-88 “improves survival” for late-stage pancreatic cancer patients. Despite this claim, the study did not include a control group, and the Company was comparing its results with historical control data. Based on this news, shares of Tyme fell by more than 35% on the same day.

If you are a shareholder who suffered a loss, please visit https://schallfirm.com/join-action-form/?slug=tyme-technologies-inc&id=1716

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at https://schallfirm.com/, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specialises in securities class action lawsuits and shareholder rights litigation.